Gallagher Cam — SEC insider filings
SEC reporting owner CIK 1557832. 59 insider filings on record with FilingPulse; latest filed 2026-09-08.
Transaction summary — filings shown
Covers the 50 most recent of 59 filings on record, filed 2021-02-03 to 2026-09-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 164,000 shares, $323,693 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 108 legs across 35 filings — 439,197 shares, $18,360,729 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
- Largest priced transaction: sale of 22,714 shares @ $43.41 ($985,917) in Zentalis Pharmaceuticals, Inc., filed 2021-04-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | President, Interim CFO, Director | 38 | — | 108 legs · 439,197 sh · $18,360,729 | 13 |
| Opus Genetics, Inc. (IRD) | Director | 12 | 2 legs · 164,000 sh · $323,693 | — | 18 |
Insider filings — Gallagher Cam
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Opus Genetics, Inc. (IRD) | Option exercise (M): 784,314 @ $1.15 · Option exercise (M): 784,314 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Opus Genetics, Inc. (IRD) | Grant/award (A): 24,367 @ $0 | EDGAR |
| 2026-01-08 | 4 | Opus Genetics, Inc. (IRD) | Grant/award (A): 67,000 @ $0 | EDGAR |
| 2025-12-31 | 4 | Opus Genetics, Inc. (IRD) | Purchase (P): 81,000 @ $1.98 · Purchase (P): 83,000 @ $1.97 · Grant/award (A): 33,000 @ $0 | EDGAR |
| 2025-08-27 | 4 | Opus Genetics, Inc. (IRD) | Grant/award (A): 869,565 @ $1.15 | EDGAR |
| 2025-05-02 | 4 | Opus Genetics, Inc. (IRD) | Grant/award (A): 79,504 @ $0 · Grant/award (A): 79,592 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Opus Genetics, Inc. (IRD) | Grant/award (A): 784,314 · Grant/award (A): 784,314 (derivative) | EDGAR |
| 2024-06-13 | 4 | Ocuphire Pharma, Inc. (OCUP) | Grant/award (A): 41,143 @ $0 · Grant/award (A): 35,181 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 9,597 @ $11.98 | EDGAR |
| 2024-02-12 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 1,173 @ $11.44 | EDGAR |
| 2024-02-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 192,500 @ $0 · Sale (S): 11,552 @ $11.54 · Grant/award (A): 192,500 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Ocuphire Pharma, Inc. (OCUP) | Grant/award (A): 10,976 @ $0 · Grant/award (A): 9,639 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 9,242 @ $26.40 · Sale (S): 18,526 @ $26.21 | EDGAR |
| 2023-02-14 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,332 @ $20.42 · Sale (S): 8,501 @ $19.96 | EDGAR |
| 2023-02-06 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 9,428 @ $22.22 · Sale (S): 572 @ $23.04 | EDGAR |
| 2023-02-01 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 161,092 @ $0 · Grant/award (A): 233,908 (derivative) @ $0 | EDGAR |
| 2023-01-18 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 9,500 @ $24.11 · Sale (S): 500 @ $24.87 | EDGAR |
| 2023-01-06 | 4 | Ocuphire Pharma, Inc. (OCUP) | Option exercise/expiry (X): 1,574 @ $0.00 · Option exercise/expiry (X): 1,574 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 9,700 @ $21.01 · Sale (S): 300 @ $21.46 | EDGAR |
| 2022-11-15 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 11,600 @ $22.72 · Sale (S): 900 @ $23.48 | EDGAR |
| 2022-11-08 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 12,343 @ $23.66 · Sale (S): 157 @ $24.24 · Sale (S): 12,374 @ $23.56 | EDGAR |
| 2022-10-17 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 12,500 @ $23.51 | EDGAR |
| 2022-10-07 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 7,004 @ $21.92 · Sale (S): 5,496 @ $22.83 · Sale (S): 10,000 @ $22.62 | EDGAR |
| 2022-09-16 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 8,426 @ $25.10 · Sale (S): 4,074 @ $25.59 · Sale (S): 8,866 @ $24.38 · Sale (S): 1,134 @ $24.99 | EDGAR |
| 2022-06-15 | 4 | Ocuphire Pharma, Inc. (OCUP) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-05-31 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 111,072 @ $0 · Grant/award (A): 333,218 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 4,369 @ $49.72 · Sale (S): 3,335 @ $50.68 · Sale (S): 2,196 @ $51.59 · Sale (S): 100 @ $52.70 | EDGAR |
| 2022-03-16 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 4,578 @ $41.45 · Sale (S): 5,322 @ $42.31 · Sale (S): 100 @ $43.18 | EDGAR |
| 2022-03-08 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 9,477 @ $44.90 · Sale (S): 523 @ $45.56 | EDGAR |
| 2022-02-15 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,264 @ $51.22 · Sale (S): 5,366 @ $52.15 · Sale (S): 1,370 @ $52.74 | EDGAR |
| 2022-02-14 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 8,203 @ $0 · Grant/award (A): 7,595 @ $0 · Sale (S): 2,079 @ $50.16 · Sale (S): 259 @ $50.75 · Sale (S): 4,850 @ $50.17 · Grant/award (A): 19,245 (derivative) @ $0 | EDGAR |
| 2022-02-07 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,290 @ $52.77 · Sale (S): 6,460 @ $53.51 · Sale (S): 1,250 @ $54.35 | EDGAR |
| 2022-01-19 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,434 @ $61.71 · Sale (S): 3,424 @ $62.37 · Sale (S): 1,842 @ $63.45 · Sale (S): 1,300 @ $64.66 | EDGAR |
| 2022-01-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,397 @ $73.18 · Sale (S): 900 @ $73.92 · Sale (S): 700 @ $75.32 · Sale (S): 3,641 @ $76.03 · Sale (S): 1,106 @ $76.90 · Sale (S): 1,156 @ $78.24 · +1 more | EDGAR |
| 2021-12-16 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,001 @ $71.28 · Sale (S): 1,100 @ $72.01 · Sale (S): 1,900 @ $73.35 · Sale (S): 1,117 @ $74.50 · Sale (S): 311 @ $76.07 · Sale (S): 520 @ $77.24 · +2 more | EDGAR |
| 2021-12-07 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 10,000 @ $71.33 | EDGAR |
| 2021-11-16 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 6,614 @ $75.02 · Sale (S): 2,400 @ $75.76 · Sale (S): 986 @ $76.67 | EDGAR |
| 2021-11-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,506 @ $82.09 · Sale (S): 5,094 @ $82.98 · Sale (S): 2,400 @ $83.79 | EDGAR |
| 2021-10-04 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 1,900 @ $64.71 · Sale (S): 2,664 @ $65.77 · Sale (S): 4,820 @ $66.77 · Sale (S): 616 @ $67.37 | EDGAR |
| 2021-09-02 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 6,241 @ $67.23 · Sale (S): 3,759 @ $68.01 | EDGAR |
| 2021-08-03 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,784 @ $49.94 · Sale (S): 4,812 @ $51.35 · Sale (S): 1,100 @ $52.59 · Sale (S): 304 @ $53.47 | EDGAR |
| 2021-07-08 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,796 @ $46.78 · Sale (S): 769 @ $47.17 · Sale (S): 54 @ $48.83 · Sale (S): 664 @ $46.08 · Sale (S): 1,050 @ $47.28 · Sale (S): 858 @ $47.76 · +3 more | EDGAR |
| 2021-07-06 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,823 @ $49.18 · Sale (S): 5,977 @ $49.80 · Sale (S): 200 @ $50.86 | EDGAR |
| 2021-06-09 | 4 | Ocuphire Pharma, Inc. (OCUP) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-02 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 8,728 @ $53.97 · Sale (S): 1,272 @ $54.61 | EDGAR |
| 2021-05-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 1,200 @ $57.08 · Sale (S): 1,992 @ $58.08 · Sale (S): 1,004 @ $59.43 · Sale (S): 5,804 @ $60.07 | EDGAR |
| 2021-04-06 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 22,714 @ $43.41 · Sale (S): 165 @ $43.26 · Sale (S): 5,399 @ $43.37 · Sale (S): 58 @ $44.21 · Sale (S): 33 @ $45.06 | EDGAR |
| 2021-03-03 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 10,000 @ $41.69 | EDGAR |
| 2021-02-16 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 8,750 @ $0 · Grant/award (A): 5,000 @ $0 · Grant/award (A): 26,250 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4/A | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,103 @ $54.77 · Sale (S): 6,597 @ $55.50 · Sale (S): 5,700 @ $56.56 · Sale (S): 3,073 @ $57.22 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1557832 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs